Related references
Note: Only part of the references are listed.Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity
Taro Okazaki et al.
CLINICAL CANCER RESEARCH (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples
E. Giovannetti et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2008)
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2007)
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
Sunil Krishnan et al.
CANCER (2007)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
Florence Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism
Emiko Sugiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
Sun Young Rha et al.
ONCOLOGIST (2007)
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
Gerold Bepler et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells
LP Jordheim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy
E. P. Tamm et al.
ABDOMINAL IMAGING (2006)
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
Woo Sun Kwon et al.
PHARMACOGENETICS AND GENOMICS (2006)
Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1
Scott N. Myers et al.
PHARMACOGENETICS AND GENOMICS (2006)
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival
V Sebastiani et al.
CLINICAL CANCER RESEARCH (2006)
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer
A Jimeno et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter
SM Fitzgerald et al.
HUMAN GENETICS (2006)
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)
Su-Ryang Kim et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
Severe drug toxicity associated with a single-nucleotide polymorphisrn of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin
K Yonemori et al.
CLINICAL CANCER RESEARCH (2005)
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients
R Rosell et al.
CLINICAL CANCER RESEARCH (2004)
Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer
H Achiwa et al.
CANCER SCIENCE (2004)
Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients
JY Shi et al.
PHARMACOGENETICS (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines
JD Davidson et al.
CANCER RESEARCH (2004)
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway
AK Fukunaga et al.
PHARMACOGENOMICS JOURNAL (2004)
Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1
DH Osato et al.
PHARMACOGENETICS (2003)
A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity
LJ Yue et al.
PHARMACOGENETICS (2003)
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
AM Bergman et al.
DRUG RESISTANCE UPDATES (2002)
Share Paper
